E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/20/2005 in the Prospect News Biotech Daily.

Millipore cut by Merrill Lynch to neutral

Millipore Corp. was downgraded by Merrill Lynch analyst Darryl Pardi to neutral from buy in light of an intra-day price of $63.40 per share, which was above Merrill's price target of $61. After raising EPS estimates for Millipore early Wednesday, Merrill said the surge in the stock was a surprise since the company reported mixed second-quarter results. Millipore shares Wednesday gained $4.33, or 7.40%, to $62.83 on volume of 1,694,400 shares versus the three-month running average of 454,173 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.